EFSA’s FEEDAP Panel found weaknesses in the data underlying the JECFA assessment which would undermine any proposal for a maximum residue level for ractopamine. The Panel found that the study on cardiovascular effects in humans cannot be taken as a basis to derive an Acceptable Daily Intake (ADI) of 0-1 micrograms per kilogramme of body weight per day as proposed by JECFA. EFSA consulted the Community Reference Laboratory responsible for beta-agonists and the European Medicines Agency (EMEA) and included the results of this process in its final opinion.
http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902437175.htm